Cargando…
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive...
Autores principales: | Sabatino, Joseph J., Mittl, Kristen, Rowles, William, Mcpolin, Kira, Rajan, Jayant V., Zamecnik, Colin R., Dandekar, Ravi, Alvarenga, Bonny D., Loudermilk, Rita P., Gerungan, Chloe, Spencer, Collin M., Sagan, Sharon A., Augusto, Danillo G., Alexander, Jessa, Hollenbach, Jill A., Wilson, Michael R., Zamvil, Scott S., Bove, Riley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475959/ https://www.ncbi.nlm.nih.gov/pubmed/34580672 http://dx.doi.org/10.1101/2021.09.10.21262933 |
Ejemplares similares
-
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
por: Sabatino, Joseph J., et al.
Publicado: (2022) -
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators
por: Sabatino, Joseph J., et al.
Publicado: (2023) -
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021) -
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
por: Bajwa, Hamza Mahmood, et al.
Publicado: (2022) -
Fluctuating and Geographically Specific Selection Characterize Rapid Evolution of the Human KIR Region
por: Augusto, Danillo G., et al.
Publicado: (2019)